Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narsoplimab in pediatric HSCT-TMA
NCT05855083Phase 2Recruiting
- Sponsor
- Omeros Corporation
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of narsoplimab in thrombotic microangiopathy (TMA), sponsored by Omeros Corporation. Started May 2023; status: recruiting.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT05855083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855083.